Skip to main
ABT
ABT logo

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 31 analyst ratings
Buy
Strong Buy 35%
Buy 45%
Hold 16%
Sell 3%
Strong Sell 0%

Bulls say

Abbott Laboratories reported strong performance in its Medical Device division, with sales reaching $5.05 billion, up 14% year-over-year, indicating robust market demand, particularly in electrophysiology and the Structural Heart portfolio, which experienced a notable 22.6% organic growth. The company's commitment to growth is further reflected in its expectation for 2025 organic sales growth of 7.5-8.5%, excluding COVID-19 testing-related sales, demonstrating resilience in advancing other product segments such as Core Laboratory Diagnostics and Nutrition. Additionally, Abbott's long-standing commitment to increasing dividends for nearly 50 consecutive years, alongside a payout ratio of 46% and a yield of 1.8%, underscores its stable financial position and shareholder value focus.

Bears say

Abbott Laboratories faces significant challenges that contribute to a negative outlook on its stock, primarily driven by declining revenues from Covid-19 testing, which fell from $8.4 billion in 2022 to only $1.6 billion in 2023. Additionally, macroeconomic pressures such as inflation and foreign exchange fluctuations are expected to hinder financial performance, with the company projecting these issues to negatively impact results in 2025. Furthermore, Abbott's reliance on international markets, which account for approximately 60% of its sales, coupled with geopolitical risks and potential changes in healthcare legislation, adds additional uncertainty to its growth prospects.

Abbott Labs (ABT) has been analyzed by 31 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 45% recommend Buy, 16% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 31 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.